Download PDF
Semin Respir Crit Care Med 2016; 37(05): 771-782
DOI: 10.1055/s-0036-1592298
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Immunotherapy for Lung Cancer: No Longer an Abstract Concept

Kristen A. Marrone
1   Division of Upper Aerodigestive, Department of Oncology, Sidney Kimmel Cancer Center at Johns Hopkins University, Baltimore, Maryland
,
Jarushka Naidoo
1   Division of Upper Aerodigestive, Department of Oncology, Sidney Kimmel Cancer Center at Johns Hopkins University, Baltimore, Maryland
,
Julie R. Brahmer
1   Division of Upper Aerodigestive, Department of Oncology, Sidney Kimmel Cancer Center at Johns Hopkins University, Baltimore, Maryland
› Author Affiliations
Further Information

Publication History

Publication Date:
12 October 2016 (online)

    Permissions and Reprints

Abstract

The treatment paradigm for lung cancer has been transformed in recent years by the use of immunotherapy, specifically, immune checkpoint antibodies (mAb), which are agents designed to reinvigorate an immune-mediated anticancer response by releasing the effects of tumor-mediated immunosuppression. Late-phase clinical trials of these agents in patients with advanced lung cancers have translated into improved clinical outcomes compared with standard-of-care chemotherapy for the treatment of metastatic non-small cell lung cancer, and have resulted in FDA approvals for two immune checkpoint mAbs in the second-line setting. In addition, promising results have been seen in early-phase clinical studies in small cell lung cancer (SCLC) and for immune checkpoint combinations in NSCLC thus far. While the efficacy of these agents is exciting, they have also been associated with a unique profile of immune-mediated toxicity that is distinct from classic cytotoxic therapies. As these agents move into the lung cancer clinic, we must seek to maximize the therapeutic potential of this class of agents through optimization of patient selection, improved response assessments, and exploring rational combinations of immune checkpoint mAbs with other potentially synergistic therapies, to improve response rates and extend the “tail on the curve.”

Keywords

immunotherapy - immune checkpoint antibody - anti-CTLA-4 - anti-PD-1 - anti-PD-L1 - non-small cell lung cancer - small cell lung cancer - lung cancer
 

  • References

  • 1 Stat Fact Sheets SEER. Lung and Bronchus Cancer. National Institutes of Health, 2015. Available at: http://seer.cancer.gov/statfacts/html/lungb.html . Accessed March 20, 2016
    PubMedGoogle Scholar
  • 2 Cell N-S. Lung Cancer v4. 2016. Available at: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf . Accessed March 20, 2016
    PubMedGoogle Scholar
  • 3 Schiller JH, Harrington D, Belani CP , et al; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346 (2) 92-98
    CrossrefPubMedGoogle Scholar
  • 4 Scagliotti GV, Parikh P, von Pawel J , et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26 (21) 3543-3551
    CrossrefPubMedGoogle Scholar
  • 5 Sandler A, Gray R, Perry MC , et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355 (24) 2542-2550
    CrossrefPubMedGoogle Scholar
  • 6 Socinski MA, Bondarenko I, Karaseva NA , et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 2012; 30 (17) 2055-2062
    CrossrefPubMedGoogle Scholar
  • 7 Patel JD, Socinski MA, Garon EB , et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol 2013; 31 (34) 4349-4357
    CrossrefPubMedGoogle Scholar
  • 8 Paz-Ares LG, de Marinis F, Dediu M , et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013; 31 (23) 2895-2902
    CrossrefPubMedGoogle Scholar
  • 9 Paz-Ares L, de Marinis F, Dediu M , et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012; 13 (3) 247-255
    CrossrefPubMedGoogle Scholar
  • 10 Barlesi F, Scherpereel A, Rittmeyer A , et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol 2013; 31 (24) 3004-3011
    CrossrefPubMedGoogle Scholar
  • 11 Lindeman NI, Cagle PT, Beasley MB , et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 2013; 137 (6) 828-860
    CrossrefPubMedGoogle Scholar
  • 12 Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res 2015; 4 (1) 36-54
    PubMedGoogle Scholar
  • 13 Shaw AT, Ou SH, Bang YJ , et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014; 371 (21) 1963-1971
    CrossrefPubMedGoogle Scholar
  • 14 Shaw AT, Gandhi L, Gadgeel S , et al; study investigators. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol 2016; 17 (2) 234-242
    CrossrefPubMedGoogle Scholar
  • 15 Shaw AT, Kim DW, Nakagawa K , et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368 (25) 2385-2394
    CrossrefPubMedGoogle Scholar
  • 16 Shaw AT, Kim DW, Mehra R , et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014; 370 (13) 1189-1197
    CrossrefPubMedGoogle Scholar
  • 17 Soda M, Choi YL, Enomoto M , et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448 (7153) 561-566
    CrossrefPubMedGoogle Scholar
  • 18 Mok TS, Wu YL, Thongprasert S , et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361 (10) 947-957
    CrossrefPubMedGoogle Scholar
  • 19 Sequist LV, Yang JC, Yamamoto N , et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31 (27) 3327-3334
    CrossrefPubMedGoogle Scholar
  • 20 Shepherd FA, Rodrigues Pereira J, Ciuleanu T , et al; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353 (2) 123-132
    CrossrefPubMedGoogle Scholar
  • 21 Rosell R, Carcereny E, Gervais R , et al; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13 (3) 239-246
    CrossrefPubMedGoogle Scholar
  • 22 Fossella FV, DeVore R, Kerr RN , et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18 (12) 2354-2362
    CrossrefPubMedGoogle Scholar
  • 23 Shepherd FA, Dancey J, Ramlau R , et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18 (10) 2095-2103
    CrossrefPubMedGoogle Scholar
  • 24 Hanna N, Shepherd FA, Fossella FV , et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22 (9) 1589-1597
    CrossrefPubMedGoogle Scholar
  • 25 Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3 (11) 991-998
    CrossrefPubMedGoogle Scholar
  • 26 Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12 (4) 252-264
    CrossrefPubMedGoogle Scholar
  • 27 Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015; 33 (17) 1974-1982
    CrossrefPubMedGoogle Scholar
  • 28 Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271 (5256) 1734-1736
    CrossrefPubMedGoogle Scholar
  • 29 Hamid O, Schmidt H, Nissan A , et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 2011; 9: 204
    CrossrefPubMedGoogle Scholar
  • 30 Melosky B, Chu Q, Juergens R, Leighl N, McLeod D, Hirsh V. Pointed progress in second-line advanced non-small-cell lung cancer: the rapidly evolving field of checkpoint inhibition. J Clin Oncol 2016; 34 (14) 1676-1688
    CrossrefPubMedGoogle Scholar
  • 31 Hodi FS, O'Day SJ, McDermott DF , et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363 (8) 711-723
    CrossrefPubMedGoogle Scholar
  • 32 Weber JS, D'Angelo SP, Minor D , et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16 (4) 375-384
    CrossrefPubMedGoogle Scholar
  • 33 Robert C, Long GV, Brady B , et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372 (4) 320-330
    CrossrefPubMedGoogle Scholar
  • 34 Robert C, Schachter J, Long GV , et al; KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372 (26) 2521-2532
    CrossrefPubMedGoogle Scholar
  • 35 Larkin J, Chiarion-Sileni V, Gonzalez R , et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373 (1) 23-34
    CrossrefPubMedGoogle Scholar
  • 36 Topalian SL, Hodi FS, Brahmer JR , et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366 (26) 2443-2454
    CrossrefPubMedGoogle Scholar
  • 37 Brahmer JR, Tykodi SS, Chow LQ , et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366 (26) 2455-2465
    CrossrefPubMedGoogle Scholar
  • 38 Brahmer JR, Drake CG, Wollner I , et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28 (19) 3167-3175
    CrossrefPubMedGoogle Scholar
  • 39 Ribas A, Kefford R, Marshall MA , et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013; 31 (5) 616-622
    CrossrefPubMedGoogle Scholar
  • 40 Zatloukal P, Seo DS, Park K , et al. Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). Annual Meeting of American Society of Clinical Oncology; 2009
    PubMedGoogle Scholar
  • 41 Gettinger SN, Horn L, Gandhi L , et al. Overall survival and long-term safety of nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015; 33 (18) 2004-2012
    CrossrefPubMedGoogle Scholar
  • 42 FDA Expands Approved Use of Opdivo in Advanced Lung Cancer. 2015. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm466413.htm . Accessed March 1, 2016
    PubMedGoogle Scholar
  • 43 FDA Approves Keytruda for Advanced Non-Small Cell Lung Cancer. 2015. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm465444.htm . Accessed March 1, 2016
    PubMedGoogle Scholar
  • 44 Rizvi NA, Mazières J, Planchard D , et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015; 16 (3) 257-265
    CrossrefPubMedGoogle Scholar
  • 45 Brahmer J, Reckamp KL, Baas P , et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373 (2) 123-135
    CrossrefPubMedGoogle Scholar
  • 46 Borghaei H, Paz-Ares L, Horn L , et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373 (17) 1627-1639
    CrossrefPubMedGoogle Scholar
  • 47 Hamid O, Robert C, Daud A , et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369 (2) 134-144
    CrossrefPubMedGoogle Scholar
  • 48 Garon EB, Rizvi NA, Hui R , et al; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372 (21) 2018-2028
    CrossrefPubMedGoogle Scholar
  • 49 Herbst RS, Baas P, Kim DW , et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387 (10027) 1540-1550
    CrossrefPubMedGoogle Scholar
  • 50 Herbst RS, Soria JC, Kowanetz M , et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515 (7528) 563-567
    CrossrefPubMedGoogle Scholar
  • 51 Fehrenbacher L, Spira A, Ballinger M , et al; POPLAR Study Group. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016; 387 (10030) 1837-1846
    CrossrefPubMedGoogle Scholar
  • 52 Rizvi N, Brahmer J, Ou S , et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). Annual American Society of Clinical Oncology Meeting; 2015
    PubMedGoogle Scholar
  • 53 Gulley J, Spigel D, Kelly K , et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: A phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy. Annual American Society of Clinical Oncology Meeting; 2015
    PubMedGoogle Scholar
  • 54 Akbay EA, Koyama S, Carretero J , et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013; 3 (12) 1355-1363
    CrossrefPubMedGoogle Scholar
  • 55 Gettinger S, Chow LQ, Borghaei H , et al. Safety and response with nivolumab (Anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (Pts) with epidermal growth factor receptor mutant (EGFR MT) advanced non-small cell lung cancer (NSCLC). Int J Radiat Oncol 2014; 90 (5) S34-S35
    PubMedGoogle Scholar
  • 56 Creelan B, Chow L, Kim DW , et al. Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC). Annual American Society of Clinical Oncology Meeting; 2015.
    PubMedGoogle Scholar
  • 57 Rizvi NA, Hellmann MD, Brahmer JR , et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2016; Sep 1; 34 (25) 2969-2979
    CrossrefPubMedGoogle Scholar
  • 58 Antonia S, Brahmer J, Gettinger S , et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). Annual American Society of Clinical Oncology Meeting; 2014
    PubMedGoogle Scholar
  • 59 Papadimitrakopoulou V, Patnaik A, Borhaei H , et al. Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C. Annual American Society of Clinical Oncology Meeting; 2015
    PubMedGoogle Scholar
  • 60 Liu S, Powderly JD, Camide DR , et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Annual American Society of Clinical Oncology Meeting; 2015
    PubMedGoogle Scholar
  • 61 Antonia S, Goldberg SB, Balmanoukian A , et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol 2016; 17 (3) 299-308
    CrossrefPubMedGoogle Scholar
  • 62 Hellmann MD, Gettinger S, Goldman JW. CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. J Clin Oncol 2016;34: (Suppl; abstr 3001)
    PubMedGoogle Scholar
  • 63 Patnaik A, Socinski M, Gugens M , et al. Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D. Annual American Society of Clinical Oncology Meeting; 2015
    PubMedGoogle Scholar
  • 64 Antonia SJ, López-Martin JA, Bendell J , et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016; 17 (7) 883-895
    CrossrefPubMedGoogle Scholar
  • 65 Hoos A. Evolution of end points for cancer immunotherapy trials. Ann Oncol 2012; 23 (Suppl. 08) viii47-52
    PubMedGoogle Scholar
  • 66 Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 2015; 33 (31) 3541-3543
    CrossrefPubMedGoogle Scholar
  • 67 Hodi FS, Hwu WJ, Kefford R , et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 2016; 34 (13) 1510-1517
    CrossrefPubMedGoogle Scholar
  • 68 Wolchok JD, Kluger H, Callahan MK , et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369 (2) 122-133
    CrossrefPubMedGoogle Scholar
  • 69 Wolchok JD, Hoos A, O'Day S , et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15 (23) 7412-7420
    CrossrefPubMedGoogle Scholar
  • 70 Hoos A, Wolchok JD, Humphrey RW, Hodi FS. CCR 20th anniversary commentary: immune-related response criteria—capturing clinical activity in immuno-oncology. Clin Cancer Res 2015; 21 (22) 4989-4991
    CrossrefPubMedGoogle Scholar
  • 71 Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J Clin Oncol 2015; 33 (18) 2092-2099
    CrossrefPubMedGoogle Scholar
  • 72 Naidoo J, Page DB, Li BT , et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015; 26 (12) 2375-2391
    PubMedGoogle Scholar
  • 73 Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30 (21) 2691-2697
    Google Scholar
  • 74 Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 2015; 76-83
    PubMedGoogle Scholar
  • 75 Teply BA, Lipson EJ. Identification and management of toxicities from immune checkpoint-blocking drugs. Oncology (Williston Park) 2014; 28 (Suppl. 03) 30-38
    PubMedGoogle Scholar
  • 76 Merck. Keytruda (pembrolizumab) prescribing information. 2015
    PubMedGoogle Scholar
  • 77 Opdivo (nivolumab): Immune-Mediated Adverse Reactions Management Guide. 2016. Available at: http://www.opdivohcp.bmscustomerconnect.com/servlet/servlet.FileDownload?file=00Pi000000Hj19REAR . Accessed March 1, 2016
    PubMedGoogle Scholar
  • 78 Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. 2010. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x211.pdf . Accessed March 1, 2016
    PubMed
  • 79 Naidoo J, Cunningham J, Woo KM , et al. Pneumonitis with anti-PD-1/PD-L1 Therapy. The European Cancer Conference; 2015; Vienna, Austria: European Journal of Cancer
    PubMedGoogle Scholar
  • 80 Naidoo J, Wang X, Woo K. Pneumonitis in patients treated with anti-PD-1/PD-L1 therapy. J Clin Oncol 2016; ; In press
    PubMedGoogle Scholar
  • 81 Rizvi NA, Hellmann MD, Snyder A , et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348 (6230) 124-128
    CrossrefPubMedGoogle Scholar
  • 82 Le DT, Uram JN, Wang H , et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372 (26) 2509-2520
    CrossrefPubMedGoogle Scholar
  • 83 Snyder A, Makarov V, Merghoub T , et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371 (23) 2189-2199
    CrossrefPubMedGoogle Scholar
  • 84 Garon EB, Leighl N, Rizvi N , et al. Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). Annual American Society of Clinical Oncology; 2014
    Google Scholar
  • 85 Hellmann MD, Creelan BC, Woo K , et al. Smoking history and response to nivolumab in patients with advanced NSCLCs. Annual European Society for Medical Oncology Meeting; 2014
    PubMedGoogle Scholar
  • 86 Dubin K, Callahan MK, Ren B , et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun 2016; 7: 10391
    CrossrefPubMedGoogle Scholar
  • 87 Sivan A, Corrales L, Hubert N , et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015; 350 (6264) 1084-1089
    CrossrefPubMedGoogle Scholar
  • 88 Vétizou M, Pitt JM, Daillère R , et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015; 350 (6264) 1079-1084
    CrossrefPubMedGoogle Scholar
  • 89 Antonia S, Gettinger S, Man Chow L , et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. Annual American Society of Clinical Oncology Meeting; 2014
    PubMedGoogle Scholar
  • 90 Carthon BC, Wolchok JD, Yuan J , et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 2010; 16 (10) 2861-2871
    CrossrefPubMedGoogle Scholar
  • 91 Lynch TJ, Bondarenko I, Luft A , et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012; 30 (17) 2046-2054
    CrossrefPubMedGoogle Scholar